Graft Versus Host Disease Gvhd clinical trials

Explore recruiting graft versus host disease gvhd clinical trials.

Recruiting graft versus host disease gvhd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Graft Versus Host Disease Gvhd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 2 Trial to determine the efficacy of belumosudil for patients with steroid-refractory overlap of syndrome Graft-versus-Host-Disease (SR-osGVHD) - BEAT-GVHD

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease

Netherlands, Italy, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, open-label, randomized, phase II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allogeneic hematopoietic stem cell transplantation treated with decidua stromal cells (DSC) or best available treatment (BAT)

Sweden, Norway, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II multicenter single-armed study using subject-specific minimal residual minimal disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myleodysplastic syndrome - MDS

Sweden, Norway, Finland, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Graft Versus Host Disease Gvhd trials by city

Graft Versus Host Disease Gvhd in Toronto Graft Versus Host Disease Gvhd in Vancouver Graft Versus Host Disease Gvhd in Montreal Graft Versus Host Disease Gvhd in Calgary Graft Versus Host Disease Gvhd in Edmonton Graft Versus Host Disease Gvhd in Ottawa Graft Versus Host Disease Gvhd in Winnipeg Graft Versus Host Disease Gvhd in Quebec City Graft Versus Host Disease Gvhd in Hamilton Graft Versus Host Disease Gvhd in Kitchener Graft Versus Host Disease Gvhd in London Graft Versus Host Disease Gvhd in Halifax Graft Versus Host Disease Gvhd in New York Graft Versus Host Disease Gvhd in Los Angeles Graft Versus Host Disease Gvhd in Chicago Graft Versus Host Disease Gvhd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease